Acelyrin, Inc. Insider Sells Shares: Key Highlights

On March 17th, Amar Murugan, an insider at Acelyrin, Inc. (NASDAQ:SLRN), executed a sale of 3,913 shares of the company’s stock. The shares were sold at an average price of $2.74, culminating in a total transaction value of $10,721.62. Following this transaction, Amar Murugan holds a total of 121,587 shares in Acelyrin, which is currently valued at around $333,148.38. This recent sale amounts to a 3.12% decrease in Murugan's holdings within the company. The transaction was formally reported in a legal filing with the Securities and Exchange Commission (SEC), accessible for public viewing.

Recent Trading Activity

Amidst this news, Acelyrin's stock experienced a decline of 1.1% during midday trading on Wednesday, with shares reaching $2.79. The trading volume was measured at 850,761 shares, lower than the company's average trading volume of 1,234,757. Currently, Acelyrin holds a market capitalization of approximately $279.91 million. Its price-to-earnings (P/E) ratio is recorded at -1.13, and it has a beta of 1.25. Over the past year, the stock has reached a low of $1.85 and a high of $8.59, with its 50-day and 200-day simple moving averages standing at $2.25 and $3.85, respectively.

In its latest quarterly earnings report published on March 19th, Acelyrin reported an earnings per share (EPS) of ($0.79), which was notably better than analyst expectations of ($0.86), beating the estimates by $0.07. Predictions indicate that Acelyrin, Inc. will likely post earnings of -$2.53 per share for the ongoing fiscal year.

Analyst Ratings and Market Insights

The stock has received attention from several research analysts recently. Citigroup lowered its price target for Acelyrin from $6.00 to $3.00, awarding it a "neutral" rating. Similarly, HC Wainwright also revised its price target downwards from $8.00 to $6.00, maintaining a "neutral" stance. In contrast, Wells Fargo & Company reduced their price objective from $15.00 to $13.00 and classified the stock as "overweight." Currently, three analysts have a hold rating while two analysts recommend buying Acelyrin's shares, leading to an overall consensus rating of "Hold" with an average price target of $9.60.

Institutional Activity in Acelyrin

Institutional investors have shown various levels of interest in Acelyrin. Intech Investment Management LLC has recently acquired a stake during the third quarter, valued at around $77,000. Charles Schwab Investment Management Inc. has increased its stake in Acelyrin by 81.4%, now controlling 609,678 shares, following the purchase of an additional 273,604 shares. Acuta Capital Partners LLC also entered the third quarter by acquiring shares worth $1,795,000. Meanwhile, Martingale Asset Management L P joined in by purchasing a new stake valued at approximately $485,000. Verition Fund Management LLC raised its stake in Acelyrin by 55.1%, adding 39,100 shares during the last quarter and now holds 110,115 shares worth $543,000. Overall, institutional investors now hold about 87.31% of Acelyrin's total shares.

About Acelyrin, Inc.

Acelyrin, Inc. is a clinical biopharmaceutical company focused on the identification, acquisition, development, and commercialization of transformative medications. Its leading product candidate is izokibep, a novel small protein therapeutic aimed at inhibiting IL-17A, which is currently advancing through Phase 3 clinical trials for treating conditions such as Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as undergoing Phase 2 trials for Axial Spondyloarthritis.

Acelyrin, Insider, Shares